Article Figures & Data
Figures
- FIGURE 1.
Examples of negative and positive amyloid PET scans using 3 FDA-approved 18F tracers. Each tracer has its own specific guidelines for image interpretation, and cases are displayed here according to those recommendations. They all share the same basic principles for image interpretation. Negative scans show white matter pattern of uptake. Positive scans show uptake in both gray and white matter and thus loss of white matter pattern. (Courtesy of Society of Nuclear Medicine and Molecular Imaging Clinical Trials Network.)
- FIGURE 2.
Schematic diagram of cumulative phases of amyloid aggregation in AD with respective antibodies currently in clinical trials that bind them. Names of clinical trials are listed next to respective antibodies being tested in amyloid-positive, cognitively normal subjects.
- FIGURE 3.
Schematic combining AD clinical diagnostic continuum with correlated biomarker progression using A/T/I/N framework.
